Spinal cord temperature as a measure of neuroinflammation in the human spinal cord

The lack of effective treatment options for neurological disorders underlines the critical need to identify new drug targets. Neuroinflammation is one of the most common disease mechanisms in various neurological disorders, which makes it a promising target for novel therapies. One of the major barriers facing the development of effective therapies that improve function in individuals with neurological disorders, such as spinal cord injury and multiple sclerosis, is the lack of suitable biomarkers. To address this issue, we aim to develop “spinal cord thermometry” or SCT. SCT can be done in awake individuals using data acquired from a non-invasive MRI scan. SCT, we believe, may provide valuable information on the degree of inflammation ongoing in the injured spinal cord. This is, conceptually, very similar to how body temperature indicates if you have an infection. Our study will develop the necessary methods to measure SCT, first in healthy individuals, before application in individuals with spinal cord injury and multiple sclerosis. Our research will provide a novel biomarker of neuroinflammation in the spinal cord and help identify ways to treat diseases associated with neuroinflammation.

Combatting infectious diseases through understanding epigenetic interference – A case study: SARS-CoV-2

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has caused 6.5 M deaths globally. Despite currently available vaccines and treatments, we need more effective therapeutics to combat the ongoing SARS-CoV-2 pandemic which remains a major global health and economic challenge.

RNAaemia (a high level of viral RNA in the blood) is a predictor of poor health outcomes in COVID-19. Therefore, the MOD-RNA pipeline was developed to analyze RNA produced by SARS-CoV-2, but in a manner consistent with the principle that RNA is the epicenter of genetic information. My research reveals SARS-CoV-2 produces small RNAs with an affinity for human genome enhancer regions. These findings support that SARS-CoV-2 has evolved epigenetic interference to promote viral propagation by abrogating transcriptional networks critical to the infection process.

To facilitate ongoing surveillance of SARS-CoV-2 variants of concern, I plan to continue building out MOD-RNA as an open-access tool, which will also be broadly applicable to other current and emerging pathogens. This research and further development of MOD-RNA is critical to our fight against SARS-CoV-2 because of the potential to find new therapeutic opportunities against COVID-19.

Advancing understanding of the multiple sclerosis (MS) prodrome: a focus on understudied signs and symptoms (MS-Pro-Us)

Multiple sclerosis likely begins years before the first neurological symptom. During this period, it can present as a set of yet to be well-defined, subtle symptoms, leading patients to increasingly seek medical attention years before actual MS symptom onset, and diagnosis. Our aim is to better understand the earliest signs of MS. We will look for poorly understood signs and symptoms such as sleep disturbances, palpitations, shortness of breath, and skin conditions among others that may appear months or years before MS onset. We will see if these signs are different in men and women and how such differences vary across different age groups. In addition, previous studies suggested that women who developed MS had fewer pregnancies and increased contraceptive use in the five years before MS onset. This may reflect lifestyle changes even before MS onset. We will look at all these issues in more depth than has ever been done before. We will have access to health data from large populations so that we can look in detail at people with and without MS. Our aim is to help doctors and researchers recognize when MS actually starts and to help doctors, patients and families get prompt, appropriate treatment for everyone who develops MS.

Team-based postpartum and infant care models: effects on service use, outcomes, and health system costs in the one year after birth

The months following childbirth may be difficult for new parents caring for a new baby (or babies) while recovering from pregnancy and birth. Team-based maternity care draws on the strengths of interprofessional teams (physicians, midwives and allied health) to improve patient care and outcomes and is a current provincial priority in British Columbia (BC). Midwifery care provides frequent post-delivery contacts, at-home care, and on-call support during this critical postpartum period. There is a growing trend in BC towards informal team-based arrangements where midwives support mother-infant dyads after physician-attended birth. In other settings, up to 18% of postpartum individuals and 8% of newborns visited the emergency department in the postpartum 6-week period. We will examine whether interprofessional team-based partnerships in which midwives provide postpartum care is associated with hospital service use (emergency department visits, hospital readmissions), maternal or infant outcomes, and health system costs in British Columbia. Findings will inform knowledge users in health policy and system leadership positions by evaluating this aspect of team-based maternity care applied in the postpartum period.

Mosquito taste receptors for detecting human sweat and initiating blood feeding

The World Health Organization estimates around 725,000 mosquito related deaths a year. This makes mosquitoes one of the deadliest animals on Earth. Mosquitoes bite us humans to get nutrients and pass deadly diseases to us as a consequence. It is well studied that mosquitoes rely on their sense of smell to find us. Yet, what tiggers them to bite us once they land on our skin is unknown. We hypothesize that mosquitoes use their sense of taste to trigger the biting behaviour. In addition, taste receptors on their legs play a crucial role in triggering biting. We will test this by first identifying which receptors will respond to human sweat. This will be done by presenting individual receptors with human sweat and identifying the ones that respond. We will then follow up by removing these receptors from the legs of mosquitoes to see if they will still bite. This will allow us to find the receptors that trigger the biting behaviour in mosquitoes. With this information, we can find safe compounds to deter mosquito biting. We can also design mosquitoes that are bad at biting to be released into the wild to produce offspring that are bad at biting as well. A combination of these methods can protect us from mosquito diseases.

Age-related impacts of the intestinal microbiota on multiple sclerosis: defining mechanisms of neurodegeneration

Progressive Multiple Sclerosis (pMS) is a prevalent neurodegenerative illness in Canada. Unfortunately, people living with pMS have limited treatment options. Age is a strong risk factor for MS progression, indicating that biological changes that occur with age could contribute to pMS-related neurodegeneration. All forms of MS show associations with the microbiome, and the microbiome undergoes substantial changes during aging. However, whether age-related changes to the gut microbiota are important contributors to the neurodegeneration seen in pMS remains undefined. Thus, I will perform fecal microbiota transplant (FMT) of samples collected from healthy aged vs young people into microbiota-depleted mice, followed by treatment to induce a laboratory form of MS. This experimental set-up allows me to isolate the role of an aged vs young microbiota on MS outcomes. In preliminary studies, mice harboring an aged microbiome develop pMS-like disease. I will identify specific microbes and the molecules they produce in aged FMT mice that exacerbate neurodegeneration. These studies will lead to better understanding of the mechanisms driving neurodegeneration in pMS, and the identification of new targets for this treatment-resistant disease.

Harnessing NK cell mechanics for fine-tuning cancer immunotherapy

Cells of the immune system help maintain health and defence against cancer by detecting and killing cancer cells in the human body. Immunotherapy is a cancer treatment strategy that boosts the immune system to fight cancer using native immune cells made in the body. Natural killer (NK) cells are a subpopulation of immune cells. NK cell-based immunotherapy has gained attention for cancer treatment due to the relatively simple procedure, although their low efficacy remains a challenge, despite many breakthroughs. An NK cell has a sophisticated molecular architecture that dynamically changes when interacting with neighbouring and target cells. When NK cells encounter cancer cells, their molecular architecture is changed to enhance their ability to combat cancer. However, details of how this happens are not entirely understood, limiting our ability to engineer them for fighting cancer. I will study the properties of cellular structures under the stimuli of weak or strong immune responses to find the best cellular architecture for cancer immunotherapy. An understanding of structural change during immune response will provide valuable information to devise a novel strategy for cancer treatment.

HIV prevention for underserved men who have sex with men: a community-based mixed methods exploration of access needs and preferences

Oral HIV prevention medications are highly effective and available at no-cost to clinically eligible patients in British Columbia. Men who have sex with men (MSM) remain a key population at a higher risk of HIV infection. However, studies suggest that certain sub-groups of MSM who would benefit from these medications are currently underserved. For example, MSM who identify as bisexual or heterosexual may be especially unlikely to use oral HIV prevention medications, leaving them and their sexual partners at higher HIV risk. Through analysis of community health survey data and one-to-one interviews with MSM in BC, my project will identify barriers to using PrEP among underserved MSM. I will explore their opinions about and preferences for different forms of HIV prevention, including oral and long-acting injectable forms of these medications. My research will help healthcare providers, community organizations and public health bodies to better understand the HIV prevention needs of underserved MSM. It will enable them to reach underserved MSM with information about ideal HIV prevention options, and to improve HIV prevention among this population, reducing the burden of HIV for these men and their partners.

Characterizing the pain needs of structurally vulnerable palliative care patients with substance use disorder

An important part of palliative care is managing pain, including physical, emotional, mental and spiritual suffering. However, people with substance use disorder (SUD), who experience homelessness and poverty (for example), face barriers in having their pain needs met. These unmet needs are due to gaps between palliative and substance use care, and because this group of people face social and health care barriers that limit their access to resources and support. Unmanaged pain among this group can have significant consequences, including suffering at the end of life and increasing risk of negative health outcomes, such as overdose. This study will examine the pain needs of palliative patients with SUD, gaps in the management of pain for this population and develop approaches to meet these needs. Research activities include interviews with palliative care patients with SUD and service providers, observations in care settings, and mapping tools to understand the broader scope of the topic. By making connections between pain management approaches among palliative and substance use health care, this research will generate new ideas to improve the management of pain among palliative care patients with SUD.

Leveraging longitudinal COVID-19 vaccine cohorts to deconstruct SARS-CoV-2-specific adaptive immune responses and the potential for viral infection to induce immune amnesia

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in >400 million documented infections and ~6 million deaths worldwide. Safe and effective vaccines have significantly reduced morbidity and mortality due to COVID-19, but even the newest bivalent vaccines provide only limited protection against infection with current SARS-CoV-2 variants. Further in-depth analyses of immune responses to COVID-19 vaccines and SARS-CoV-2 infection are needed. Moreover, the rise in non-COVID-19 respiratory infections in 2022 has led to speculation that SARS-CoV-2 may impair immune responses to other pathogens. This is plausible since SARS-CoV-2 can dysregulate B cells, the specialized immune cells that produce antibodies, but few studies have examined this. My research will examine the generation of B cell responses against the original (ancestral) SARS-CoV-2 and newer Omicron variants in a diverse cohort of vaccinated adults. I will characterize B cells that cross-react with ancestral and variant Spike, which are likely to help protect against new strains. Finally, I will explore the consequences of SARS-CoV-2 infection on B cell responses to other respiratory viruses.